A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes

Trial Profile

A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Insulin aspart/insulin protamine aspart; Metformin; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ACTION
  • Most Recent Events

    • 20 May 2009 Actual patient numbers amended from 200 to 230 as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual end date (1 Aug 2005) added as reported by ClinicalTrials.gov.
    • 01 Jan 2009 Results have been published in Diabetes, Obesity and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top